Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of July 2017
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X
Form
40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __ No
X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule
12g3-2(b): 82-_____________
3
July 2017 07:00 BST
ASTRAZENECA COMPLETES AGREEMENT
WITH RECORDATI FOR SELOKEN IN EUROPE
AstraZeneca
announced today that it has completed* the previously-communicated
agreement with Recordati S.p.A (Recordati) for the commercial
rights to Seloken/Seloken ZOK (metoprolol tartrate and
metoprolol succinate, respectively) and associated
Logimax fixed-dose
combination (metoprolol succinate and felodipine) medicines in
Europe. Metoprolol succinate is a beta-blocker for the control of
hypertension, angina and heart failure.
Based
on the limited level of ongoing interest that AstraZeneca will
retain in the medicines in Europe, the upfront and tiered royalty
payments received from Recordati will be reported as Other
Operating Income in the Company's financial statements. An upfront
payment of $290 million will be accounted for in the second quarter
of 2017.
*With the exception of Romania,
which is subject to separate closing.
About AstraZeneca
AstraZeneca
is a global, science-led biopharmaceutical company that focuses on
the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three main
therapy areas - Oncology, Cardiovascular & Metabolic Diseases
and Respiratory. The Company also is selectively active in the
areas of autoimmunity, neuroscience and infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit www.astrazeneca.com and
follow us on Twitter @AstraZeneca.
|
Media Relations
|
|
|
|
Esra Erkal-Paler
|
UK/Global
|
+44 203 749 5638
|
|
Karen Birmingham
|
UK/Global
|
+44 203 749 5634
|
|
Rob Skelding
|
UK/Global
|
+44 203 749 5821
|
|
Jacob Lund
|
Sweden
|
+46 8 553 260 20
|
|
Michele Meixell
|
US
|
+1 302 885 2677
|
|
Investor Relations
|
|
|
|
Thomas Kudsk Larsen
|
|
+44 203 749 5712
|
|
Craig Marks
|
Finance, Fixed Income, M&A
|
+44 7881 615 764
|
|
Henry Wheeler
|
Oncology
|
+44 203 749 5797
|
|
Mitchell Chan
|
Oncology
|
+1 240
477 3771
|
|
Lindsey Trickett
|
Cardiovascular & Metabolic Diseases
|
+1 240
543 7970
|
|
Nick Stone
|
Respiratory
|
+44 203 749 5716
|
|
Christer Gruvris
|
Autoimmunity, Neuroscience & Infection
|
+44 203 749 5711
|
|
US toll free
|
|
+1 866
381 7277
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
AstraZeneca
PLC
|
Date:
03 July 2017
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|